(RTTNews) - AstraZeneca (AZN, AZN.L, ZEG.DE, AZN.ST) said positive high-level results from the SANOVO Phase III trial in China demonstrated Tagrisso plus Orpathys showed a statistically significant and highly clinically meaningful improvement in progression-free survival versus T
AstraZeneca Reports Positive Results Of SANOVO Phase III Trial In China
By Dhallo News · September 1, 2026 at 11:59 AM IST
Original reporting: NasdaqRead original report →
Have feedback on this article?Report error or suggestion
